期刊文献+

定量检测HBsAg和HBeAg在干扰素治疗HBeAg阳性慢性乙肝疗效中的预测价值 被引量:1

Prediction Value of HBsAg and HBeAg in the Therapeutic Effect of Interferon on HBeAg Positive Chronic Hepatitis B
下载PDF
导出
摘要 【目的】探讨定量检测血清乙肝表面抗原(HBsAg)和乙型肝炎病毒e抗原(HBeAg)水平的动态变化在预测干扰素治疗HBeAg阳性慢性乙肝疗效中的价值。【方法】回顾性分析2011-2014年在上海市公共卫生临床中心接受聚乙二醇干扰素a-2a(PEG-IFNa-2a)治疗的47例慢性乙型肝炎患者的临床资料。治疗48~72周,每周一次,每次180pg,治疗结束后随访24周,根据持续病毒学应答(SVR)标准将患者分为SVR组和非SVR组。治疗前、治疗12周、治疗24周分别定量检测血清HBsAg和HBeAg水平,观察两组患者相关指标的动态变化。【结果】治疗第12周及随访24周,SVR组患者血清HBeAg水平均显著低于非SVR组,差异具有统计学意义(P〈0.05);随访第24周SVR组患者血清HBsAg水平显著低于非SVR组,差异具有统计学意义(P〈0.05)。SVR组患者血清HBeAg、HBsAg水平下降幅度均大于非SVR组患者,差异具有统计学意义(P〈0.05)。ROC曲线分析发现24周时HBeAg水平有最佳的预测价值。【结论]HBsAg和HBeAg水平均对干扰素疗效有较好的预测价值,但HBeAg优于HBsAg。 [Objective]To investigate the dynamic changes of serum hepatitis B surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) levels for the prediction of the therapeutic effect of interferon on HBeAg positive chronic hepatitis B. [Methods]The clinical data of 47 patients with chronic hepatitis B treated by(PEG-IFNa-2a in the Public Health Center of Shanghai were analyzed retrospectively. Treatment :48-72 weeks, onee/week,180μg,24 weeks of follow-up after treatment. According to the criteria for sustained viral response (SVR), patients were divided into the SVR group and the non SVR group. The levels of serum HBsAg and HBeAg of pre-treatment, 12 weeks and 24 weeks post treatment were detected respectively, and the dynamic changes of the related indexes of the two groups were observed. [Results]In the twelfth week of treatment and 24-week follow-up , the level of serum HBeAg in patients of the SVR group was significantly lower than that in the non SVR group, the difference was statistically significant( P〈0.05) In twenty-fourth week of follow-up, the level of serum HBsAg of the SVR group was significantly lower than that in the non SVR group, the difference was statistically significant( P 〈0.05). The decreasing rate of serum HBeAg and HBsAg levels in the SVR group were significantly higher than those in the non SVR group, the difference was statistically significant ( P 〈0.05). Roe curve analysis showed that the HBeAg level had the best predictive value at 24th week.[Conclusion] Both HBsAg and HBeAg have good predictive value on the efficacy of interferon, while HBeAg is better than HBsAg.
出处 《医学临床研究》 CAS 2015年第9期1674-1676,共3页 Journal of Clinical Research
基金 上海市卫生和计划生育委员会资助(基金编号:2010111)
关键词 肝炎表面抗原 乙型/血液 肝炎E抗原 乙型/血液 干扰素类/治疗应用 肝炎 乙型 慢性/药物疗法 Hepatitis B Surface Antigens/BL~ Hepatitis B e Antigens/BL Interferons/TU Hepatitis B, Chronic/DT
  • 相关文献

参考文献12

  • 1Chan HL,Wong VW, Chim AM, et al .Serum HBsAg quan-tification to predict response to peginterferon therapy of e an-tigen positive chronic hepatitis B[J]. Aliment PharmacolTher, 2010,32(11-12):1323-1331.
  • 2Brunetto MR, Moriconi F, Bonino F, et al . Hepatitis B vi-rus surface antigen levels: a guide to sustained response topeginterferon alfa -2 a in HBeAg-negative chronic hepatitis B[J]. Hepatology , 2009,49(4) :1141.
  • 3慢性乙型肝炎防治指南(2010年版)[J].实用肝脏病杂志,2011,14(2):81-89. 被引量:437
  • 4Naito H,Hayashi S,Abe K. Rapid and specific genotypingsystem for hepatitis B virus corresponding to six major geno-types by PCR using type-specific primers [J]. J ClinMicrobiol, 2001,39(1): 362-364.
  • 5ter Borg MJ, van Zonneveid M, Zeuzem S, et al . Patterns ofViral decline during PEG-Interferon alpha-2b therapy inHBeAg-Positive chronic hepatitis B: relation to treatment re-sponse[J]. Hepatology . 2006,44(3) :721-727.
  • 6Fried MW,Piratvisuth T, Lau GK, et al . HBeAg and hepa-titis B virus DNA as outcome predictors during therapy withpeginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]_ Hepatology , 2008,47(2) :428-434.
  • 7Liaw YF,Jia JD,Chan HL, et al . Shorter durations andlower doses of peginterferon alfa-2a are associated with inferi-or hepatitis B e antigen seroconversion rates in hepatitis B vi-rus genotypes B or C[J]. Hepatology , 2011, 54 C 5) : 1591-1599.
  • 8Lau GK, Marcellin P, Brunetto et al . On-treatment mo-nitoring of HBsAg levels to predict response to peginterferon-alfa-2a in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2009,50(Suppl 1): S333.
  • 9肖宏,张文宏.乙型肝炎病毒表面抗原和e抗原定量检测对聚乙二醇干扰素治疗慢性乙型肝炎疗效的预测价值[J].微生物与感染,2012,7(4):255-259. 被引量:5
  • 10Chan HLY, Wong VWS. Wong GLH, et al . Early hepatitisB virus DNA suppression can predict virologie response topeginterferon and lamivudine treatment [ J ]. ClinGastroenterol Hepatol,2008,6(9):1022-1026.

二级参考文献20

  • 1ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL, HBV 99-01 Study Group. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B.. relation to treatment response [J]. Hepatology, 2006, 44 (3) : 721-727.
  • 2Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia [J]. J Hepatol, 2010, 52 (4): 508-513.
  • 3Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response [J]. Clin Gastroenterol Hepatol, 2007, 5 (12) :1462-1468.
  • 4Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B [J]. Hepatology, 2010, 52(4) :1232-1241.
  • 5Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitisB using HBsAg and HBV DNA levels [J]. Hepatology, 2010, 52(2) :454-461.
  • 6Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline [J]. Hepatology, 2010, 52(4):1251-1257.
  • 7Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers [J]. Gastroenterology, 2010, 139(2) :483-490.
  • 8Gane E, Jia J, Han K, Tanwandee T, Chuang WL, Marcellin P, Chan HL, Piratvisuth T, Wat C, Martins E, Liaw YF. NEPTUNE Study: On-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients [J]. J Hepatol, 2011, 54:S31.
  • 9Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B [J]. Aliment Pharmacol Ther, 2010, 32 (11-12): 1323-1331.
  • 10Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline [J]. Hepatology, 2010, 52(4) : 1251-1257.

共引文献440

同被引文献5

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部